Advanced Solid Tumors
Conditions
Keywords
Solid Tumors Transforming Growth Factor Beta Activin Receptor-like Kinase 1
Brief summary
The purpose of this study is to test the safety and effectiveness of PF-03446962 when given as a single agent. Tumors require new blood vessels to support their ability to grow and to spread (metastasize). New treatments aimed at preventing these blood vessels have the ability to improve the clinical management of cancer.
Interventions
DRUGPF-03446962
To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
Sponsors
Pfizer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Advanced measurable or non-measurable solid tumors * Adequate bone marrow function * Adequate liver function * Adequate renal function * Be able and willing to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures
Exclusion criteria
* Chemotherapy, radiotherapy, or any investigational cancer therapy within 4 weeks of first dose of study medication * Active bleeding disorder, including gastrointestinal bleeding, as evidenced by hematemesis, hemoptysis or melena in the past 6 months * Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident including transient ischemic attack, or pulmonary embolus; or any other active thromboembolic event * QTc prolongation defined as QTc \>450 msec * Patients with known brain metastasis * Patients with peritoneal carcinosis at risk of bleeding * Major surgical procedure within 4 weeks of treatment * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD): Part 1 | Baseline up to 42 days after the start of each increased treatment dose | MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT and at least 2 out of 3/6 participants in the next higher dose. DLT was defined as any of the following events occurring during the first 42 days of study drug: any grade greater than or equal to 3 hematologic and non-hematologic toxicity, all non-disease-related adverse events (AEs). |
| Recommended Phase 2 Dose (RP2D): Part 1 | Baseline up to 42 days after the start of each increased treatment dose | RP2D was defined as the lower dose level to MTD based on the safety profile. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Cycle 1 of Day 1 up to 28 days after the last dose of treatment | AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Seriousness of an AE was assessed as serious adverse event (SAE) and non-serious adverse event (non-SAE). An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Non-SAE included all AE minus SAE. Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
| Time to Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Cycle 1 of Day 1 up to 28 days after the last dose of treatment | Total time from onset of adverse event till the event is resolved. Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
| Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Cycle 1 of Day 1 up to 28 days after the last dose of treatment | Laboratory tests included hematology (hemoglobin, lymphocytes absolute \[abs\], neutrophils abs, platelets, white blood cells) and chemistry (alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hyponatremia, hypophosphatemia, lipase). Assays were based on National Cancer Institute \[NCI\] Common Terminology Criteria for AE (CTCAE) grading scale for AEs (grade 1 \[mild AE: did not cause any significant problem, no dose adjustment required\]; grade 2 \[moderate AE: caused problem that did not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event\]; grade 3 \[severe AE: caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event\] and grade 4 \[life threatening AE\]). Overall data of the 4 grades is reported. |
| Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Cycle 1 of Day 1 up to 28 days after the last dose of treatment | An all causality AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs was any untoward medical occurrence in participant that was attributed to study drug. Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
| Percentage of Participants With Disease Control: Part 2 | Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490 | Participants who achieved either a confirmed complete Response or confirmed partial response or a Stable disease lasting at least 12 weeks from the first dose was defined as achieving disease control. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all target lesions and non-target lesions. PR: \>=30 % decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD and stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as a reference the smallest sum of the LD according to RECIST associated to non-progressive disease response for non-target lesions. Percentage of participants achieving disease control was calculated out of the participants participating in the exploratory phase. |
| Time To Progression (TTP): Part 2 | Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490 | Time in months from start of treatment to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of treatment plus 1) divided by 30.44. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST). PD: \>=20% increase in the sum of the LD of the target lesions taking as a reference the smallest sum of the LD or the appearance of one or more new lesions and as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesions. TTP was calculated out of the participants participating in the exploratory phase. |
| Volume of Distribution: Part 1 and Part 2 | 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms) | Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. As per planned analysis, volume of distribution was summarized if at least 3 participants had reportable value. |
| Percentage of Participants With Objective Response: Part 1 and Part 2 | Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490 | Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR defined as disappearance of all target lesions and non-target lesions. PR defined as \>=30 % decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non-target lesions. |
| Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Cycle 1 of Day 1 up to 28 days after the last dose of treatment | AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity; Grade 0 (no change from normal); grade 1 (mild AE which did not cause any significant problem, no dose adjustment required); grade 2 (moderate AE which caused problem that did not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event); grade 3 (severe AE which caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event); grade 4 (life threatening AE) and grade 5 (death). Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490) | Plasma concentrations of soluble proteins (VEGF-C, VEGF-d, VEGFR1) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. |
| Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms) | — |
| Circulating Endothelial Cells (CEC)and Circulating Endothelial Progenitors (CEP): Part 1 and Part 2 | Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490) | Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Blood samples for the assessment of CECs and circulating CEPs were collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs. Circulating Cells were classified as CEPs if cluster differentiation 133 positive cells (CD133+) were detected. |
| Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490) | Plasma concentrations of soluble proteins (VEGFR2, VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. |
| Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | 0 hr (pre dose), 1 hr post-dose C1D1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to C12 | — |
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms) | — |
| Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms) | AUC (0-28) = Area under the plasma concentration versus time curve from time zero (pre-dose) to Day 28 (0-28). |
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms) | Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). |
| Systemic Clearance(CL): Part 1 and Part 2 | 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms) | CL is a quantitative measure of the rate at which a drug substance is removed from the body. As per planned analysis, CL was summarized if at least 3 participants had reportable value. |
| Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms) | Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. As per planned analysis, t1/2 was summarized if at least 3 participants had reportable value. |
| Human Anti - Human Antibody (HAHA) Concentration: Part 1 and Part 2 | Baseline up to 3 months after last dose | HAHA concentration was analyzed in blood samples for the evaluation of immunogenicity of PF-03446962. HAHA concentration was reported for samples above lower limit of quantification (\>=4.32). |
| Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490) | Plasma concentrations of soluble proteins (Ang-2, BMP-9, C-C motif) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. |
| Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490) | Plasma concentrations of soluble proteins (CD106, CD54 and Endoglin) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. |
| Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490) | Plasma concentrations of soluble proteins (PLGF, TGFB1, VEGF-A) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. |
Countries
Italy, South Korea, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| PF-03446962 All participants who received PF-03446962 intravenous infusion (0.5 milligram/kilogram \[mg/kg\], 1 mg/kg, 2 mg, 3 mg/kg, 4.5 mg/kg, 6.75 mg/kg, 10 mg/kg, 15 mg/kg, 7 mg/kg), on Day 1 of cycle 1 (28 days) and on Day 1 of subsequent cycles (14 days) until disease progression or unacceptable toxicity. | 68 |
| Total | 68 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 |
|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: Dose Escalation Phase | Adverse Event | 1 | 0 | 1 | 1 | 1 | 3 | 1 | 2 | 0 |
| Part 1: Dose Escalation Phase | Death | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Part 1: Dose Escalation Phase | global deterioration of health status | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| Part 1: Dose Escalation Phase | objective progression or relapse | 3 | 5 | 3 | 1 | 3 | 2 | 5 | 3 | 0 |
| Part 1: Dose Escalation Phase | Other | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| Part 1: Dose Escalation Phase | randomized but not treated | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part 1: Dose Escalation Phase | Withdrawal by Subject | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Part 2: Exploratory Phase | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Part 2: Exploratory Phase | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Part 2: Exploratory Phase | global deterioration of health status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Part 2: Exploratory Phase | objective progression or relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 |
| Part 2: Exploratory Phase | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Part 2: Exploratory Phase | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | PF-03446962 |
|---|---|
| Age, Continuous | 61.3 years STANDARD_DEVIATION 11.5 |
| Sex: Female, Male Female | 24 Participants |
| Sex: Female, Male Male | 44 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 68 / 68 |
| serious Total, serious adverse events | 24 / 68 |
Outcome results
Primary
Maximum Tolerated Dose (MTD): Part 1
MTD was defined as highest dose level for which no more than 1 participant in a dose cohort experienced DLT and at least 2 out of 3/6 participants in the next higher dose. DLT was defined as any of the following events occurring during the first 42 days of study drug: any grade greater than or equal to 3 hematologic and non-hematologic toxicity, all non-disease-related adverse events (AEs).
Time frame: Baseline up to 42 days after the start of each increased treatment dose
Population: The MTD analysis set included all participants who were enrolled in the dose escalation part of the study and received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PF-03446962 | Maximum Tolerated Dose (MTD): Part 1 | 10.0 milligram/kilogram (mg/kg) |
Primary
Recommended Phase 2 Dose (RP2D): Part 1
RP2D was defined as the lower dose level to MTD based on the safety profile.
Time frame: Baseline up to 42 days after the start of each increased treatment dose
Population: The MTD analysis set included all participants who were enrolled in the dose escalation part of the study and received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PF-03446962 | Recommended Phase 2 Dose (RP2D): Part 1 | 7.0 mg/kg |
Secondary
Number of Participants With Laboratory Abnormalities: Part 1 and Part 2
Laboratory tests included hematology (hemoglobin, lymphocytes absolute \[abs\], neutrophils abs, platelets, white blood cells) and chemistry (alanine aminotransferase, alkaline phosphatase, amylase, aspartate aminotransferase, bilirubin, creatinine, hypercalcemia, hyperglycemia, hyperkalemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hyponatremia, hypophosphatemia, lipase). Assays were based on National Cancer Institute \[NCI\] Common Terminology Criteria for AE (CTCAE) grading scale for AEs (grade 1 \[mild AE: did not cause any significant problem, no dose adjustment required\]; grade 2 \[moderate AE: caused problem that did not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event\]; grade 3 \[severe AE: caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event\] and grade 4 \[life threatening AE\]). Overall data of the 4 grades is reported.
Time frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
Population: Safety population included all enrolled participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 2 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 4 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 4 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 0 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 0 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 4 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 0 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 0 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 1 participants |
| PF-03446962 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 1 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 1 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 1 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 4 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 1 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 1 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 1 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 4 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 3 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 3 participants |
| PF-03446962 1 mg/kg | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 2 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 1 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 1 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 1 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 4 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 2 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 5 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 6 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 2 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 2 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 2 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 2 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 1 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 3 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 4 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 2 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 2 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 2 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 2 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 1 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 1 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 2 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 4 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 3 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 1 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 2 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 2 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 3 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 2 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 1 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 2 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 2 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 1 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 0 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 3 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 2 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 1 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 4 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 0 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 2 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 1 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 1 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 2 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 3 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 2 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 5 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 4 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 5 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 5 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 2 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 4 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 1 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 1 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 2 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 6 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 3 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 1 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 2 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 2 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 5 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 3 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 3 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 3 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 2 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 6 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 4 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 3 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 2 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 5 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 2 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 2 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 5 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 2 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 1 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 5 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 2 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 5 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 2 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 2 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 4 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 6 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 5 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 2 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoglycemia | 0 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypernatremia | 1 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lymphocytes abs | 12 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperkalemia | 5 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypokalemia | 7 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyponatremia | 17 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hemoglobin | 20 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | White blood cells | 4 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hyperglycemia | 23 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Aspartate Aminotransferase | 20 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypercalcemia | 1 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypophosphatemia | 10 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Lipase | 7 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Bilirubin | 11 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alanine Aminotransferase | 18 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Amylase | 6 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Alkaline Phosphatase | 20 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypoalbuminemia | 12 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Creatinine | 10 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Hypocalcemia | 6 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Platelets | 12 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Laboratory Abnormalities: Part 1 and Part 2 | Neutrophils abs | 3 participants |
Secondary
Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Seriousness of an AE was assessed as serious adverse event (SAE) and non-serious adverse event (non-SAE). An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Non-SAE included all AE minus SAE. Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
Population: Safety population included all enrolled participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| PF-03446962 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 5 participants |
| PF-03446962 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 2 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 5 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 6 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 3 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 3 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 1 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 4 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 8 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 4 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 7 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 2 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 3 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 6 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Non-Serious Adverse Events | 24 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Seriousness: Part 1 and Part 2 | Serious Adverse Events | 9 participants |
Secondary
Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AE was assessed according to severity; Grade 0 (no change from normal); grade 1 (mild AE which did not cause any significant problem, no dose adjustment required); grade 2 (moderate AE which caused problem that did not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event); grade 3 (severe AE which caused problem that interfered significantly with usual activities or the clinical status, study drug stopped due to adverse event); grade 4 (life threatening AE) and grade 5 (death). Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
Population: Safety population included all enrolled participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| PF-03446962 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 1 participants |
| PF-03446962 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 0 participants |
| PF-03446962 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 3 participants |
| PF-03446962 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 1 participants |
| PF-03446962 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 2 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 0 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 3 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 4 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 1 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 0 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 0 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 1 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 4 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 0 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 0 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 3 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 2 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 1 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 2 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 3 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 3 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 0 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 1 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 0 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 3 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 1 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 1 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 1 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 0 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 5 | 1 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 1 | 3 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 4 | 4 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 2 | 7 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment Emergent Adverse Events (AEs) Based on Severity: Part 1 and Part 2 | Grade 3 | 9 participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2
An all causality AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs was any untoward medical occurrence in participant that was attributed to study drug. Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
Population: Safety population included all enrolled participants who received at least one dose of study drug.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| PF-03446962 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 4 participants |
| PF-03446962 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 5 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 5 participants |
| PF-03446962 1 mg/kg | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 2 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 4 participants |
| PF-03446962 2 mg/kg : Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 6 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 1 participants |
| PF-03446962 3 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 3 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 3 participants |
| PF-03446962 4.5 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 4 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 8 participants |
| PF-03446962 6.75 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 7 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 6 participants |
| PF-03446962 10 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 7 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 6 participants |
| PF-03446962 15 mg/kg: Part 1 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 2 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | Treatment-related | 20 participants |
| PF-03446962 7 mg/kg: Part 2 | Number of Participants With Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2 | All causalities | 24 participants |
Secondary
Percentage of Participants With Disease Control: Part 2
Participants who achieved either a confirmed complete Response or confirmed partial response or a Stable disease lasting at least 12 weeks from the first dose was defined as achieving disease control. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all target lesions and non-target lesions. PR: \>=30 % decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD and stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as a reference the smallest sum of the LD according to RECIST associated to non-progressive disease response for non-target lesions. Percentage of participants achieving disease control was calculated out of the participants participating in the exploratory phase.
Time frame: Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
Population: Response-evaluable set included all participants who started Cycle 1 with an adequate baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PF-03446962 | Percentage of Participants With Disease Control: Part 2 | 29.2 percentage of participants |
Secondary
Percentage of Participants With Objective Response: Part 1 and Part 2
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR defined as disappearance of all target lesions and non-target lesions. PR defined as \>=30 % decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non-target lesions.
Time frame: Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
Population: Response-evaluable set included all participants who received at least 1 dose of study drug with an adequate baseline tumor assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| PF-03446962 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 0 percentage of participants |
| PF-03446962 1 mg/kg | Percentage of Participants With Objective Response: Part 1 and Part 2 | 0 percentage of participants |
| PF-03446962 2 mg/kg : Part 1 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 16.7 percentage of participants |
| PF-03446962 3 mg/kg: Part 1 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 0 percentage of participants |
| PF-03446962 4.5 mg/kg: Part 1 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 0 percentage of participants |
| PF-03446962 6.75 mg/kg: Part 1 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 0 percentage of participants |
| PF-03446962 10 mg/kg: Part 1 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 28.6 percentage of participants |
| PF-03446962 15 mg/kg: Part 1 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 0 percentage of participants |
| PF-03446962 7 mg/kg: Part 2 | Percentage of Participants With Objective Response: Part 1 and Part 2 | 0 percentage of participants |
Secondary
Time To Progression (TTP): Part 2
Time in months from start of treatment to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of treatment plus 1) divided by 30.44. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST). PD: \>=20% increase in the sum of the LD of the target lesions taking as a reference the smallest sum of the LD or the appearance of one or more new lesions and as unequivocal progression of existing non-target lesions, or the appearance of \>=1 new lesions. TTP was calculated out of the participants participating in the exploratory phase.
Time frame: Baseline then 6 weeks after Cycle 1 of Day1 thereafter every 6 weeks up to Day 490
Population: Safety population included all participants who received at least one dose of study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| PF-03446962 | Time To Progression (TTP): Part 2 | 3.0 months |
Secondary
Time to Treatment-Emergent Adverse Events (AEs): Part 1 and Part 2
Total time from onset of adverse event till the event is resolved. Treatment-emergent events were events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Cycle 1 of Day 1 up to 28 days after the last dose of treatment
Population: Data for timing was reported in individual participant listing for every adverse event (AE) and mentioned for description of narrative of Serious AEs but was not statistically summarized for analysis on the entire safety population, as planned.
Secondary
Volume of Distribution: Part 1 and Part 2
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. As per planned analysis, volume of distribution was summarized if at least 3 participants had reportable value.
Time frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962. Here N (Number of participants analyzed) signifies those who were evaluable for the measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| PF-03446962 | Volume of Distribution: Part 1 and Part 2 | 6.350 liter (L) | Standard Deviation 1.1399 |
| PF-03446962 1 mg/kg | Volume of Distribution: Part 1 and Part 2 | 5.770 liter (L) | Standard Deviation 1.185 |
| PF-03446962 2 mg/kg : Part 1 | Volume of Distribution: Part 1 and Part 2 | 7.421 liter (L) | Standard Deviation 2.8525 |
| PF-03446962 3 mg/kg: Part 1 | Volume of Distribution: Part 1 and Part 2 | NA liter (L) | — |
| PF-03446962 4.5 mg/kg: Part 1 | Volume of Distribution: Part 1 and Part 2 | NA liter (L) | — |
| PF-03446962 6.75 mg/kg: Part 1 | Volume of Distribution: Part 1 and Part 2 | 6.718 liter (L) | Standard Deviation 1.24 |
| PF-03446962 10 mg/kg: Part 1 | Volume of Distribution: Part 1 and Part 2 | 5.373 liter (L) | Standard Deviation 0.85541 |
| PF-03446962 15 mg/kg: Part 1 | Volume of Distribution: Part 1 and Part 2 | 6.675 liter (L) | Standard Deviation 2.4858 |
| PF-03446962 7 mg/kg: Part 2 | Volume of Distribution: Part 1 and Part 2 | 6.110 liter (L) | Standard Deviation 1.6303 |
Other Pre-specified
Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2
AUC (0-28) = Area under the plasma concentration versus time curve from time zero (pre-dose) to Day 28 (0-28).
Time frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962. Here N (Number of participants analyzed) signifies those who were evaluable for the measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| PF-03446962 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 490000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 132220 |
| PF-03446962 1 mg/kg | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 1752000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 436440 |
| PF-03446962 2 mg/kg : Part 1 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 3281000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 1817700 |
| PF-03446962 3 mg/kg: Part 1 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 8247000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 2657400 |
| PF-03446962 4.5 mg/kg: Part 1 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 15070000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 1447700 |
| PF-03446962 6.75 mg/kg: Part 1 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 22890000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 7372200 |
| PF-03446962 10 mg/kg: Part 1 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 45750000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 15972000 |
| PF-03446962 15 mg/kg: Part 1 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 52660000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 29315000 |
| PF-03446962 7 mg/kg: Part 2 | Area Under the Curve From Time Zero to Day 28 [AUC (0-28)]: Part 1 and Part 2 | 22890000 nanogram*hour/milliliter (ng*hr/mL) | Standard Deviation 10395000 |
Other Pre-specified
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Time frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962. Here N (Number of participants analyzed) signifies those who were evaluable for the measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| PF-03446962 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 471400 ng*hr/mL | Standard Deviation 124340 |
| PF-03446962 1 mg/kg | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 1683000 ng*hr/mL | Standard Deviation 435490 |
| PF-03446962 2 mg/kg : Part 1 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 3273000 ng*hr/mL | Standard Deviation 1819200 |
| PF-03446962 3 mg/kg: Part 1 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 8247000 ng*hr/mL | Standard Deviation 2657400 |
| PF-03446962 4.5 mg/kg: Part 1 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 15690000 ng*hr/mL | Standard Deviation 2965800 |
| PF-03446962 6.75 mg/kg: Part 1 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 21380000 ng*hr/mL | Standard Deviation 7823700 |
| PF-03446962 10 mg/kg: Part 1 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 44110000 ng*hr/mL | Standard Deviation 15577000 |
| PF-03446962 15 mg/kg: Part 1 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 51160000 ng*hr/mL | Standard Deviation 21718000 |
| PF-03446962 7 mg/kg: Part 2 | Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast): Part 1 and Part 2 | 22850000 ng*hr/mL | Standard Deviation 10504000 |
Other Pre-specified
Circulating Endothelial Cells (CEC)and Circulating Endothelial Progenitors (CEP): Part 1 and Part 2
Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Blood samples for the assessment of CECs and circulating CEPs were collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs. Circulating Cells were classified as CEPs if cluster differentiation 133 positive cells (CD133+) were detected.
Time frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
Population: Data was reported in individual participant listings but not statistically summarized due to statistical constraints.
Other Pre-specified
Human Anti - Human Antibody (HAHA) Concentration: Part 1 and Part 2
HAHA concentration was analyzed in blood samples for the evaluation of immunogenicity of PF-03446962. HAHA concentration was reported for samples above lower limit of quantification (\>=4.32).
Time frame: Baseline up to 3 months after last dose
Population: Statistical Data was not statistically summarized as majority of participants had concentration below the limit of quantification.
Other Pre-specified
Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2
Time frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| PF-03446962 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 7210 nanogram/milliliter (ng/mL) | Standard Deviation 2004 |
| PF-03446962 1 mg/kg | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 18510 nanogram/milliliter (ng/mL) | Standard Deviation 5623.4 |
| PF-03446962 2 mg/kg : Part 1 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 38090 nanogram/milliliter (ng/mL) | Standard Deviation 20361 |
| PF-03446962 3 mg/kg: Part 1 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 62530 nanogram/milliliter (ng/mL) | Standard Deviation 25484 |
| PF-03446962 4.5 mg/kg: Part 1 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 123700 nanogram/milliliter (ng/mL) | Standard Deviation 49961 |
| PF-03446962 6.75 mg/kg: Part 1 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 140600 nanogram/milliliter (ng/mL) | Standard Deviation 49562 |
| PF-03446962 10 mg/kg: Part 1 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 274500 nanogram/milliliter (ng/mL) | Standard Deviation 102100 |
| PF-03446962 15 mg/kg: Part 1 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 304000 nanogram/milliliter (ng/mL) | Standard Deviation 131350 |
| PF-03446962 7 mg/kg: Part 2 | Maximum Observed Serum Concentration (Cmax): Part 1 and Part 2 | 153100 nanogram/milliliter (ng/mL) | Standard Deviation 60116 |
Other Pre-specified
Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2
Time frame: 0 hr (pre dose), 1 hr post-dose C1D1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to C12
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962. Here N (Number of participants analyzed) signifies those who were evaluable for the measure and n signifies those participants who were evaluable at specific time-point.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 588.0 ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | NA ng/mL | — |
| PF-03446962 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 2000 ng/mL | Standard Deviation 353.55 |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | NA ng/mL | — |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 704.0 ng/mL | Standard Deviation 461.03 |
| PF-03446962 1 mg/kg | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | NA ng/mL | — |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | 11920 ng/mL | Standard Deviation 7749.9 |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | NA ng/mL | — |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | 10850 ng/mL | Standard Deviation 353.55 |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 11490 ng/mL | Standard Deviation 3691.1 |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | NA ng/mL | — |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | 20100 ng/mL | — |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | 14150 ng/mL | Standard Deviation 1626.3 |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | 1010 ng/mL | Standard Deviation 1377.1 |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 9992 ng/mL | Standard Deviation 14932 |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | 13470 ng/mL | Standard Deviation 6554.9 |
| PF-03446962 2 mg/kg : Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 6715 ng/mL | Standard Deviation 2934.5 |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | 34200 ng/mL | — |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | 4473 ng/mL | Standard Deviation 1888.6 |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 17070 ng/mL | Standard Deviation 5122.8 |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 22030 ng/mL | Standard Deviation 3931.1 |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 25930 ng/mL | Standard Deviation 5488.5 |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | NA ng/mL | — |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | 43400 ng/mL | — |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | 47500 ng/mL | — |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | 43200 ng/mL | — |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | 44200 ng/mL | — |
| PF-03446962 3 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | NA ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 4850 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | 55200 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 42200 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | 45000 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | 45000 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | 8675 ng/mL | Standard Deviation 2203 |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | 64500 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | 45100 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | 40500 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 32700 ng/mL | — |
| PF-03446962 4.5 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | 39000 ng/mL | — |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | 14820 ng/mL | Standard Deviation 4943.4 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | 52100 ng/mL | Standard Deviation 7636.8 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | 55050 ng/mL | Standard Deviation 10677 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 41880 ng/mL | Standard Deviation 3108.5 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 45850 ng/mL | Standard Deviation 15660 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 51600 ng/mL | Standard Deviation 12065 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | 59050 ng/mL | Standard Deviation 16334 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | 73670 ng/mL | Standard Deviation 24393 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | 58070 ng/mL | Standard Deviation 8471.9 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | 55150 ng/mL | Standard Deviation 11526 |
| PF-03446962 6.75 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | 76950 ng/mL | Standard Deviation 42497 |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 93130 ng/mL | Standard Deviation 44384 |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 103300 ng/mL | Standard Deviation 56589 |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | 44700 ng/mL | — |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | 217000 ng/mL | — |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | 294000 ng/mL | — |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 77530 ng/mL | Standard Deviation 31351 |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | 222000 ng/mL | — |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | 190000 ng/mL | — |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | 33440 ng/mL | Standard Deviation 14738 |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | 186000 ng/mL | — |
| PF-03446962 10 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | 44700 ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | NA ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | NA ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 87100 ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | NA ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | NA ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | NA ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | NA ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | NA ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 69400 ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 98800 ng/mL | — |
| PF-03446962 15 mg/kg: Part 1 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | 35450 ng/mL | Standard Deviation 1060.7 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 3 Day 1 (n=3, 2, 4, 3, 1, 4, 3, 1, 13) | 40870 ng/mL | Standard Deviation 25784 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 12 Day 1 (n=0, 0, 0, 0, 1, 2, 1, 0, 2) | 69200 ng/mL | Standard Deviation 71842 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 10 Day 1 (n=0, 0, 1, 1, 1, 2, 1, 0, 3) | 66620 ng/mL | Standard Deviation 50809 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 2 Day 1 (n=3, 2, 6, 3, 4, 5, 5, 2, 15) | 17230 ng/mL | Standard Deviation 8815 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 4 Day 1 (n=2, 2, 2, 3, 1, 4, 3, 1, 12) | 64960 ng/mL | Standard Deviation 35284 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 6 Day 1 (n=0, 2, 2, 1, 1, 1, 1, 0, 7) | 69250 ng/mL | Standard Deviation 52222 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 11 Day 1 (n=0, 0, 0, 1, 1, 2, 1, 0, 3) | 103600 ng/mL | Standard Deviation 78883 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 7 Day 1 (n=0, 0, 2, 1, 1, 3, 1, 0, 7) | 68100 ng/mL | Standard Deviation 56580 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 9 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 4) | 85750 ng/mL | Standard Deviation 57225 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 5 Day 1 (n= 1, 0, 2, 3, 1, 3, 3, 1, 12) | 76960 ng/mL | Standard Deviation 40711 |
| PF-03446962 7 mg/kg: Part 2 | Minimum Observed Serum Trough Concentration (Cmin): Part 1 and Part 2 | Cycle 8 Day 1 (n=0, 0, 2, 1, 1, 2, 1, 0, 5) | 99740 ng/mL | Standard Deviation 66263 |
Other Pre-specified
Plasma Decay Half-Life (t1/2): Part 1 and Part 2
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. As per planned analysis, t1/2 was summarized if at least 3 participants had reportable value.
Time frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962. Here N (Number of participants analyzed) signifies those who were evaluable for the measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| PF-03446962 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 2.678 hours | Standard Deviation 1.0622 |
| PF-03446962 1 mg/kg | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 5.588 hours | Standard Deviation 2.379 |
| PF-03446962 2 mg/kg : Part 1 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 7.360 hours | Standard Deviation 4.5596 |
| PF-03446962 3 mg/kg: Part 1 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | NA hours | — |
| PF-03446962 4.5 mg/kg: Part 1 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | NA hours | — |
| PF-03446962 6.75 mg/kg: Part 1 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 11.90 hours | Standard Deviation 0.88882 |
| PF-03446962 10 mg/kg: Part 1 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 10.22 hours | Standard Deviation 2.3394 |
| PF-03446962 15 mg/kg: Part 1 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 17.77 hours | Standard Deviation 5.6589 |
| PF-03446962 7 mg/kg: Part 2 | Plasma Decay Half-Life (t1/2): Part 1 and Part 2 | 9.616 hours | Standard Deviation 2.387 |
Other Pre-specified
Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2
Plasma concentrations of soluble proteins (Ang-2, BMP-9, C-C motif) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
Time frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
Population: Soluble protein biomarker analysis set included all participants who received at least one dose of study drug with a baseline (pre-dose C1D1) or screening biomarker result, and at least one on-treatment biomarker result for at least one biomarker. n signifies those participants who were evaluable at specific time-point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 297.0 picogram/milliliter (pg/mL) | Standard Deviation 146.98 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1466.4 picogram/milliliter (pg/mL) | Standard Deviation 510.75 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 45.7 picogram/milliliter (pg/mL) | Standard Deviation 51.45 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 1413.8 picogram/milliliter (pg/mL) | Standard Deviation 651.34 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 357.7 picogram/milliliter (pg/mL) | Standard Deviation 87.87 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 55.3 picogram/milliliter (pg/mL) | Standard Deviation 66.6 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 1048.4 picogram/milliliter (pg/mL) | Standard Deviation 259.96 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 1132.1 picogram/milliliter (pg/mL) | Standard Deviation 202.68 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 80.4 picogram/milliliter (pg/mL) | Standard Deviation 86.41 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 41.7 picogram/milliliter (pg/mL) | Standard Deviation 44.6 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 1413.1 picogram/milliliter (pg/mL) | Standard Deviation 451.52 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 47.5 picogram/milliliter (pg/mL) | Standard Deviation 52.77 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 507.2 picogram/milliliter (pg/mL) | Standard Deviation 375.16 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 309.1 picogram/milliliter (pg/mL) | Standard Deviation 133.43 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 1300.7 picogram/milliliter (pg/mL) | Standard Deviation 519.44 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 280.9 picogram/milliliter (pg/mL) | Standard Deviation 107.01 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 53.2 picogram/milliliter (pg/mL) | Standard Deviation 70.27 |
| PF-03446962 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 304.4 picogram/milliliter (pg/mL) | Standard Deviation 126.39 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 18.3 picogram/milliliter (pg/mL) | Standard Deviation 6.92 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 23.9 picogram/milliliter (pg/mL) | Standard Deviation 0.49 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 898.5 picogram/milliliter (pg/mL) | Standard Deviation 270.19 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 245.2 picogram/milliliter (pg/mL) | Standard Deviation 85.36 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 326.0 picogram/milliliter (pg/mL) | Standard Deviation 122.58 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1156.6 picogram/milliliter (pg/mL) | Standard Deviation 493.42 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 429.8 picogram/milliliter (pg/mL) | Standard Deviation 202.03 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 882.1 picogram/milliliter (pg/mL) | Standard Deviation 300.21 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 338.1 picogram/milliliter (pg/mL) | Standard Deviation 235.11 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 868.2 picogram/milliliter (pg/mL) | Standard Deviation 348.23 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 355.6 picogram/milliliter (pg/mL) | Standard Deviation 166.32 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 933.3 picogram/milliliter (pg/mL) | Standard Deviation 259.79 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 15.5 picogram/milliliter (pg/mL) | Standard Deviation 5.86 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 897.1 picogram/milliliter (pg/mL) | Standard Deviation 414.25 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 19.5 picogram/milliliter (pg/mL) | Standard Deviation 10.38 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 21.3 picogram/milliliter (pg/mL) | Standard Deviation 2.76 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 16.7 picogram/milliliter (pg/mL) | Standard Deviation 7.57 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 312.4 picogram/milliliter (pg/mL) | Standard Deviation 195.37 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1091.0 picogram/milliliter (pg/mL) | Standard Deviation 317.65 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 1019.8 picogram/milliliter (pg/mL) | Standard Deviation 222.52 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 99.4 picogram/milliliter (pg/mL) | Standard Deviation 176.84 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 729.7 picogram/milliliter (pg/mL) | Standard Deviation 242.18 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 489.7 picogram/milliliter (pg/mL) | Standard Deviation 235.28 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 439.5 picogram/milliliter (pg/mL) | Standard Deviation 292.25 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 501.2 picogram/milliliter (pg/mL) | Standard Deviation 194.4 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 67.2 picogram/milliliter (pg/mL) | Standard Deviation 114.87 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 156.4 picogram/milliliter (pg/mL) | Standard Deviation 179.39 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 54.7 picogram/milliliter (pg/mL) | Standard Deviation 112.92 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 410.2 picogram/milliliter (pg/mL) | Standard Deviation 170.55 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 60.5 picogram/milliliter (pg/mL) | Standard Deviation 121.98 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 1065.6 picogram/milliliter (pg/mL) | Standard Deviation 491.41 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 405.3 picogram/milliliter (pg/mL) | Standard Deviation 171.82 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 417.6 picogram/milliliter (pg/mL) | Standard Deviation 192.35 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 56.4 picogram/milliliter (pg/mL) | Standard Deviation 104.06 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 1296.3 picogram/milliliter (pg/mL) | Standard Deviation 629.37 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 951.0 picogram/milliliter (pg/mL) | Standard Deviation 418.52 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 248.0 picogram/milliliter (pg/mL) | Standard Deviation 84.73 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 898.4 picogram/milliliter (pg/mL) | Standard Deviation 144.11 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 205.7 picogram/milliliter (pg/mL) | Standard Deviation 48.1 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 793.2 picogram/milliliter (pg/mL) | Standard Deviation 180.32 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 645.4 picogram/milliliter (pg/mL) | Standard Deviation 94.59 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 17.1 picogram/milliliter (pg/mL) | Standard Deviation 9.9 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 258.3 picogram/milliliter (pg/mL) | Standard Deviation 57.44 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 845.5 picogram/milliliter (pg/mL) | Standard Deviation 309.44 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 16.5 picogram/milliliter (pg/mL) | Standard Deviation 2.33 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 346.7 picogram/milliliter (pg/mL) | Standard Deviation 57.94 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 1179.8 picogram/milliliter (pg/mL) | Standard Deviation 597.43 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 18.8 picogram/milliliter (pg/mL) | Standard Deviation 0 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 18.4 picogram/milliliter (pg/mL) | Standard Deviation 11.54 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 18.2 picogram/milliliter (pg/mL) | Standard Deviation 0.28 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 777.6 picogram/milliliter (pg/mL) | Standard Deviation 220.42 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 266.3 picogram/milliliter (pg/mL) | Standard Deviation 28.31 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 233.8 picogram/milliliter (pg/mL) | Standard Deviation 47.89 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 20.9 picogram/milliliter (pg/mL) | Standard Deviation 10.39 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 501.3 picogram/milliliter (pg/mL) | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 35.7 picogram/milliliter (pg/mL) | Standard Deviation 36.66 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 58.9 picogram/milliliter (pg/mL) | Standard Deviation 85.35 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 554.3 picogram/milliliter (pg/mL) | Standard Deviation 404.8 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 746.4 picogram/milliliter (pg/mL) | Standard Deviation 330.31 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 735.7 picogram/milliliter (pg/mL) | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 692.5 picogram/milliliter (pg/mL) | Standard Deviation 216.16 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 699.6 picogram/milliliter (pg/mL) | Standard Deviation 372.5 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 725.2 picogram/milliliter (pg/mL) | Standard Deviation 654.99 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 580.3 picogram/milliliter (pg/mL) | Standard Deviation 485.49 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 858.5 picogram/milliliter (pg/mL) | Standard Deviation 697.41 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 54.1 picogram/milliliter (pg/mL) | Standard Deviation 58.18 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 637.5 picogram/milliliter (pg/mL) | Standard Deviation 535.52 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 10.8 picogram/milliliter (pg/mL) | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 775.6 picogram/milliliter (pg/mL) | Standard Deviation 618.41 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 801.0 picogram/milliliter (pg/mL) | Standard Deviation 432.1 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 68.2 picogram/milliliter (pg/mL) | Standard Deviation 79.58 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 75.5 picogram/milliliter (pg/mL) | Standard Deviation 94.07 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 629.7 picogram/milliliter (pg/mL) | Standard Deviation 265.33 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1206.5 picogram/milliliter (pg/mL) | Standard Deviation 443 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 558.0 picogram/milliliter (pg/mL) | Standard Deviation 249.9 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 491.8 picogram/milliliter (pg/mL) | Standard Deviation 236.61 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 445.3 picogram/milliliter (pg/mL) | Standard Deviation 231.91 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 510.0 picogram/milliliter (pg/mL) | Standard Deviation 305.51 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 499.8 picogram/milliliter (pg/mL) | Standard Deviation 368.96 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 262.0 picogram/milliliter (pg/mL) | Standard Deviation 669.08 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 273.3 picogram/milliliter (pg/mL) | Standard Deviation 658.58 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 394.0 picogram/milliliter (pg/mL) | Standard Deviation 852.68 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 391.7 picogram/milliliter (pg/mL) | Standard Deviation 755.57 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 933.3 picogram/milliliter (pg/mL) | Standard Deviation 1593.69 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 246.1 picogram/milliliter (pg/mL) | Standard Deviation 460.69 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 1648.5 picogram/milliliter (pg/mL) | Standard Deviation 744.8 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 910.1 picogram/milliliter (pg/mL) | Standard Deviation 297.1 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 896.0 picogram/milliliter (pg/mL) | Standard Deviation 365.37 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 818.3 picogram/milliliter (pg/mL) | Standard Deviation 422.89 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 1190.4 picogram/milliliter (pg/mL) | Standard Deviation 675.67 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 254.5 picogram/milliliter (pg/mL) | Standard Deviation 44.89 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 498.4 picogram/milliliter (pg/mL) | Standard Deviation 508.76 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 1146.9 picogram/milliliter (pg/mL) | Standard Deviation 400.3 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 1176.7 picogram/milliliter (pg/mL) | Standard Deviation 198.86 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 44.0 picogram/milliliter (pg/mL) | Standard Deviation 35 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 1176.2 picogram/milliliter (pg/mL) | Standard Deviation 699.03 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 48.9 picogram/milliliter (pg/mL) | Standard Deviation 23.13 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 557.9 picogram/milliliter (pg/mL) | Standard Deviation 575.66 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 613.0 picogram/milliliter (pg/mL) | Standard Deviation 627.25 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 33.0 picogram/milliliter (pg/mL) | Standard Deviation 20.44 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 35.6 picogram/milliliter (pg/mL) | Standard Deviation 25.63 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 26.5 picogram/milliliter (pg/mL) | Standard Deviation 16.89 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 1798.7 picogram/milliliter (pg/mL) | Standard Deviation 1374.4 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 32.2 picogram/milliliter (pg/mL) | Standard Deviation 13.14 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 566.3 picogram/milliliter (pg/mL) | Standard Deviation 617.76 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 974.9 picogram/milliliter (pg/mL) | Standard Deviation 1014.67 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 858.6 picogram/milliliter (pg/mL) | Standard Deviation 165.26 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 909.9 picogram/milliliter (pg/mL) | Standard Deviation 278.5 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 400.0 picogram/milliliter (pg/mL) | Standard Deviation 198.85 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 617.1 picogram/milliliter (pg/mL) | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 17.1 picogram/milliliter (pg/mL) | Standard Deviation 7.69 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 29.0 picogram/milliliter (pg/mL) | Standard Deviation 11.38 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 737.9 picogram/milliliter (pg/mL) | Standard Deviation 572.3 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 2659.5 picogram/milliliter (pg/mL) | Standard Deviation 1356.79 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 586.8 picogram/milliliter (pg/mL) | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 1253.9 picogram/milliliter (pg/mL) | Standard Deviation 353.28 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 338.1 picogram/milliliter (pg/mL) | Standard Deviation 84.57 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 14.0 picogram/milliliter (pg/mL) | Standard Deviation 5.99 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 1061.8 picogram/milliliter (pg/mL) | Standard Deviation 469.42 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 548.1 picogram/milliliter (pg/mL) | Standard Deviation 324.7 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 600.5 picogram/milliliter (pg/mL) | Standard Deviation 469.09 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1060.8 picogram/milliliter (pg/mL) | Standard Deviation 577.85 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 12.2 picogram/milliliter (pg/mL) | Standard Deviation 4.88 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 1179.9 picogram/milliliter (pg/mL) | Standard Deviation 370.44 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 16.6 picogram/milliliter (pg/mL) | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 22.0 picogram/milliliter (pg/mL) | Standard Deviation 12.27 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: Ang-2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 1497.4 picogram/milliliter (pg/mL) | Standard Deviation 881.71 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: BMP-9 (n=5, 5, 2, 2, 4, 4, 5, 5, 17) | 33.8 picogram/milliliter (pg/mL) | Standard Deviation 27.55 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: Ang-2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 1539.3 picogram/milliliter (pg/mL) | Standard Deviation 1036.24 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: BMP-9 (n=4, 3, 6, 2, 4, 7, 7, 6, 23) | 45.0 picogram/milliliter (pg/mL) | Standard Deviation 48.97 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: CCL2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 801.9 picogram/milliliter (pg/mL) | Standard Deviation 338.56 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: CCL2 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 1743.1 picogram/milliliter (pg/mL) | Standard Deviation 1267.52 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: BMP-9 (n=3, 2, 6, 2, 4, 4, 5, 2, 20) | 40.0 picogram/milliliter (pg/mL) | Standard Deviation 51.36 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: BMP-9 (n=2, 2, 4, 2, 1, 3, 3, 1, 12) | 40.8 picogram/milliliter (pg/mL) | Standard Deviation 36.65 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C3D1: CCL2 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 791.3 picogram/milliliter (pg/mL) | Standard Deviation 364.58 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: Ang-2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 2791.2 picogram/milliliter (pg/mL) | Standard Deviation 3637.55 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: Ang-2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 1651.4 picogram/milliliter (pg/mL) | Standard Deviation 894.33 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: CCL2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 887.7 picogram/milliliter (pg/mL) | Standard Deviation 411.38 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | EOT: CCL2 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 743.7 picogram/milliliter (pg/mL) | Standard Deviation 314.64 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: BMP-9 (n=4, 5, 6, 2, 4, 5, 7, 5, 19) | 39.2 picogram/milliliter (pg/mL) | Standard Deviation 40.88 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D22: CCL2 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 846.5 picogram/milliliter (pg/mL) | Standard Deviation 524.84 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C1D16H: Ang-2 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 1509.6 picogram/milliliter (pg/mL) | Standard Deviation 813.06 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | Baseline: BMP-9 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 47.6 picogram/milliliter (pg/mL) | Standard Deviation 50.88 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Angiopoietin-2 (Ang-2), Bone Morphogenetic Protein-9 (BMP-9), Chemokine (C-C Motif) Ligand 2 (CCL2)]: Part 1 and Part 2 | C2D1: Ang-2 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1473.5 picogram/milliliter (pg/mL) | Standard Deviation 690.55 |
Other Pre-specified
Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2
Plasma concentrations of soluble proteins (CD106, CD54 and Endoglin) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
Time frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
Population: Soluble protein biomarker analysis set included all participants who received at least one dose of study drug with a baseline (pre-dose C1D1) or screening biomarker result, and at least one on-treatment biomarker result for at least one biomarker. n signifies those participants who were evaluable at specific time-point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 24503.9 pg/ml | Standard Deviation 3500.18 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 28268.0 pg/ml | Standard Deviation 7727.06 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1577290 pg/ml | Standard Deviation 378509 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 2097201 pg/ml | Standard Deviation 582243 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1508775 pg/ml | Standard Deviation 201658 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 25412.5 pg/ml | Standard Deviation 2910.37 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 24345.9 pg/ml | Standard Deviation 1067.46 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 495252 pg/ml | Standard Deviation 112929 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 22204.3 pg/ml | Standard Deviation 1736.96 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 433203 pg/ml | Standard Deviation 90282.8 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1553640 pg/ml | Standard Deviation 248023 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 24961.0 pg/ml | Standard Deviation 2310.44 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 428766 pg/ml | Standard Deviation 80302.4 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 535193 pg/ml | Standard Deviation 116435 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 1531678 pg/ml | Standard Deviation 249394 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1426995 pg/ml | Standard Deviation 59227.1 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 458194 pg/ml | Standard Deviation 64789.1 |
| PF-03446962 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 456653 pg/ml | Standard Deviation 100191 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 585405 pg/ml | Standard Deviation 46397.3 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 504828 pg/ml | Standard Deviation 53486.9 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 29688.2 pg/ml | Standard Deviation 2138.72 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 32984.2 pg/ml | Standard Deviation 691.27 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1799035 pg/ml | Standard Deviation 695018 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1782709 pg/ml | Standard Deviation 473363 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 2134392 pg/ml | Standard Deviation 357871 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1994588 pg/ml | Standard Deviation 266837 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1751998 pg/ml | Standard Deviation 131286 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1977059 pg/ml | Standard Deviation 278968 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 30123.0 pg/ml | Standard Deviation 2225.81 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 566407 pg/ml | Standard Deviation 160088 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 26852.1 pg/ml | Standard Deviation 6037.41 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 592276 pg/ml | Standard Deviation 164098 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 28133.0 pg/ml | Standard Deviation 5202.28 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 512402 pg/ml | Standard Deviation 81155.7 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 24983.9 pg/ml | Standard Deviation 5489.16 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 841543 pg/ml | Standard Deviation 568591 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 2229424 pg/ml | Standard Deviation 469152 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 27615.3 pg/ml | Standard Deviation 9426.55 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 22355.2 pg/ml | Standard Deviation 5984.52 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 21789.5 pg/ml | Standard Deviation 3978.18 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2103430 pg/ml | Standard Deviation 918193 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1997949 pg/ml | Standard Deviation 699820 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 578775 pg/ml | Standard Deviation 246897 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 23453.9 pg/ml | Standard Deviation 3631.56 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 2251447 pg/ml | Standard Deviation 517132 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 646360 pg/ml | Standard Deviation 390594 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 2465890 pg/ml | Standard Deviation 1070226 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 24944.4 pg/ml | Standard Deviation 2436.94 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 3480129 pg/ml | Standard Deviation 1753142 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 598761 pg/ml | Standard Deviation 333166 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 624061 pg/ml | Standard Deviation 233499 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 23247.5 pg/ml | Standard Deviation 5843.99 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 585420 pg/ml | Standard Deviation 308551 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1022507 pg/ml | Standard Deviation 841417 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1550000 pg/ml | Standard Deviation 637320 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1600889 pg/ml | Standard Deviation 484412 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 474589 pg/ml | Standard Deviation 70371.2 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 356495 pg/ml | Standard Deviation 54530 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 32203.6 pg/ml | Standard Deviation 5574.7 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 703255 pg/ml | Standard Deviation 486462 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 1370676 pg/ml | Standard Deviation 329573 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 450887 pg/ml | Standard Deviation 168300 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 27246.9 pg/ml | Standard Deviation 4925.02 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1409035 pg/ml | Standard Deviation 308143 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 30265.3 pg/ml | Standard Deviation 2727.69 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 28064.5 pg/ml | Standard Deviation 4097.5 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 483216 pg/ml | Standard Deviation 158483 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 375141 pg/ml | Standard Deviation 32483.6 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1269574 pg/ml | Standard Deviation 366430 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 31365.1 pg/ml | Standard Deviation 3547.94 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 31266.8 pg/ml | Standard Deviation 3466.76 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1892928 pg/ml | Standard Deviation 571192 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 26342.4 pg/ml | Standard Deviation 2922.41 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 600281 pg/ml | Standard Deviation 94835.6 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 26231.6 pg/ml | Standard Deviation 3899.05 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 2370883 pg/ml | Standard Deviation 1278663 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 3004218 pg/ml | Standard Deviation 2225879 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 2058998 pg/ml | Standard Deviation 1253058 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 628011 pg/ml | Standard Deviation 242437 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 25209.2 pg/ml | Standard Deviation 3357.89 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 565451 pg/ml | Standard Deviation 196841 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 538807 pg/ml | Standard Deviation 172168 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 2817598 pg/ml | Standard Deviation 2026342 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2317802 pg/ml | Standard Deviation 1217870 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 605375 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 590523 pg/ml | Standard Deviation 144561 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 22233.2 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 2162501 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 28094.3 pg/ml | Standard Deviation 1554.41 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 28478.7 pg/ml | Standard Deviation 5527.04 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 24736.3 pg/ml | Standard Deviation 5716.8 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 2121253 pg/ml | Standard Deviation 675955 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 24864.6 pg/ml | Standard Deviation 3830.51 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 548456 pg/ml | Standard Deviation 201218 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 29350.8 pg/ml | Standard Deviation 2213.84 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 24336.6 pg/ml | Standard Deviation 3196.96 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 612504 pg/ml | Standard Deviation 370207 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2537306 pg/ml | Standard Deviation 1097384 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 2542120 pg/ml | Standard Deviation 2147151 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 2169361 pg/ml | Standard Deviation 755936 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 24395.8 pg/ml | Standard Deviation 2414.67 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 575469 pg/ml | Standard Deviation 392901 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 2762433 pg/ml | Standard Deviation 1722911 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 664537 pg/ml | Standard Deviation 533228 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 567736 pg/ml | Standard Deviation 306989 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 537001 pg/ml | Standard Deviation 171132 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 3009982 pg/ml | Standard Deviation 2128505 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 29895.0 pg/ml | Standard Deviation 2248.59 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 27295.5 pg/ml | Standard Deviation 8538.87 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1380137 pg/ml | Standard Deviation 234263 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1096693 pg/ml | Standard Deviation 941040 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1994549 pg/ml | Standard Deviation 1151754 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1825721 pg/ml | Standard Deviation 1290987 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 2701837 pg/ml | Standard Deviation 1710834 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1676349 pg/ml | Standard Deviation 691658 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 3869570 pg/ml | Standard Deviation 2242247 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 627494 pg/ml | Standard Deviation 279501 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 603467 pg/ml | Standard Deviation 311056 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 939357 pg/ml | Standard Deviation 706017 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 641992 pg/ml | Standard Deviation 351793 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 414291 pg/ml | Standard Deviation 147170 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 26313.7 pg/ml | Standard Deviation 6449.03 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 25110.6 pg/ml | Standard Deviation 8066.23 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 33397.7 pg/ml | Standard Deviation 13366.3 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 24540.0 pg/ml | Standard Deviation 4547.98 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 38234.3 pg/ml | Standard Deviation 16532 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 890980 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 2600730 pg/ml | Standard Deviation 1098325 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 604023 pg/ml | Standard Deviation 291355 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 24970.6 pg/ml | Standard Deviation 7020.96 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 3247890 pg/ml | Standard Deviation 1683551 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 517460 pg/ml | Standard Deviation 251249 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 26855.9 pg/ml | Standard Deviation 4711.3 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 33259.2 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 569412 pg/ml | Standard Deviation 121592 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 2456276 pg/ml | Standard Deviation 1404983 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 554785 pg/ml | Standard Deviation 201270 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 2105192 pg/ml | Standard Deviation 1365510 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 27813.5 pg/ml | Standard Deviation 15243.7 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2380621 pg/ml | Standard Deviation 1221978 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 727099 pg/ml | Standard Deviation 302728 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 4814239 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 26774.1 pg/ml | Standard Deviation 11443 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 25599.5 pg/ml | Standard Deviation 7530 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: Endoglin (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 33976.7 pg/ml | Standard Deviation 9156.44 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD54 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1108796 pg/ml | Standard Deviation 416355 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD54 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 969068 pg/ml | Standard Deviation 433245 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD54 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 980791 pg/ml | Standard Deviation 354159 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: Endoglin (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 35726.0 pg/ml | Standard Deviation 8159.01 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: Endoglin (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 36010.7 pg/ml | Standard Deviation 7362.59 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD54 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 1173444 pg/ml | Standard Deviation 546999 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD54 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1053926 pg/ml | Standard Deviation 491420 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD54 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 925590 pg/ml | Standard Deviation 408338 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: Endoglin (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 37263.6 pg/ml | Standard Deviation 9744.94 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | EOT: CD106 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 6321592 pg/ml | Standard Deviation 2385497 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: CD106 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 4482748 pg/ml | Standard Deviation 2376204 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C2D1: CD106 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 5217619 pg/ml | Standard Deviation 2747474 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D22: CD106 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 5453614 pg/ml | Standard Deviation 2116043 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C3D1: Endoglin (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 35347.9 pg/ml | Standard Deviation 6702.15 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | C1D16H: CD106 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 4441245 pg/ml | Standard Deviation 2178832 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: CD106 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 4618397 pg/ml | Standard Deviation 2077485 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Cluster of Differentiation 106 (CD106), Cluster of Differentiation 54 (CD54), Endoglin]: Part 1 and Part 2 | Baseline: Endoglin (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 32680.3 pg/ml | Standard Deviation 6820.09 |
Other Pre-specified
Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2
Plasma concentrations of soluble proteins (PLGF, TGFB1, VEGF-A) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
Time frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
Population: Soluble protein biomarker analysis set included all participants who received at least one dose of study drug with a baseline (pre-dose C1D1) or screening biomarker result, and at least one on-treatment biomarker result for at least one biomarker. n signifies those participants who were evaluable at specific time-point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 564.3 pg/ml | Standard Deviation 212.89 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 991.3 pg/ml | Standard Deviation 606.54 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 11.8 pg/ml | Standard Deviation 3.15 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 907.5 pg/ml | Standard Deviation 479.21 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 8.4 pg/ml | Standard Deviation 1.56 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 9.1 pg/ml | Standard Deviation 5.69 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 9.4 pg/ml | Standard Deviation 4.81 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 216478 pg/ml | Standard Deviation 33849.2 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 160128 pg/ml | Standard Deviation 119814 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 1106.9 pg/ml | Standard Deviation 374.74 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 387504 pg/ml | Standard Deviation 211630 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 623.7 pg/ml | Standard Deviation 330.44 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 11.0 pg/ml | Standard Deviation 3.87 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 185701 pg/ml | Standard Deviation 107677 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 192856 pg/ml | Standard Deviation 167465 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 172056 pg/ml | Standard Deviation 100831 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 11.3 pg/ml | Standard Deviation 6.94 |
| PF-03446962 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 988.3 pg/ml | Standard Deviation 646.26 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 378.6 pg/ml | Standard Deviation 427.52 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 279062 pg/ml | Standard Deviation 214205 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 58530.3 pg/ml | Standard Deviation 70338.7 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 9.6 pg/ml | Standard Deviation 3.98 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 321.7 pg/ml | Standard Deviation 401.42 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 222.3 pg/ml | Standard Deviation 201.48 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 9.3 pg/ml | Standard Deviation 2.06 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 8.3 pg/ml | Standard Deviation 3.2 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 772.5 pg/ml | Standard Deviation 466.51 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 6.1 pg/ml | Standard Deviation 3.09 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 203200 pg/ml | Standard Deviation 158543 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 476.4 pg/ml | Standard Deviation 155.58 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 700.2 pg/ml | Standard Deviation 406.16 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 328947 pg/ml | Standard Deviation 271795 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 7.6 pg/ml | Standard Deviation 0.49 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 327375 pg/ml | Standard Deviation 208226 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 162468 pg/ml | Standard Deviation 63111.4 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 15.2 pg/ml | Standard Deviation 5.66 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 225230 pg/ml | Standard Deviation 129870 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 14.7 pg/ml | Standard Deviation 4.3 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 12.4 pg/ml | Standard Deviation 2.94 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 272123 pg/ml | Standard Deviation 162239 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 182580 pg/ml | Standard Deviation 112201 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 281413 pg/ml | Standard Deviation 181027 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 203631 pg/ml | Standard Deviation 254400 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 188182 pg/ml | Standard Deviation 199702 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 452.5 pg/ml | Standard Deviation 328.65 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 8.7 pg/ml | Standard Deviation 0.64 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 788.6 pg/ml | Standard Deviation 578.29 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 9.9 pg/ml | Standard Deviation 4.37 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 786.5 pg/ml | Standard Deviation 650.76 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 608.8 pg/ml | Standard Deviation 789.07 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 9.8 pg/ml | Standard Deviation 3.55 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 633.0 pg/ml | Standard Deviation 332.78 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 231.6 pg/ml | Standard Deviation 187.74 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 9.5 pg/ml | Standard Deviation 2.48 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 11.0 pg/ml | — |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 579.8 pg/ml | Standard Deviation 205.68 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 7.5 pg/ml | — |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 213943 pg/ml | Standard Deviation 64818.6 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 6.4 pg/ml | Standard Deviation 0.85 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 526.5 pg/ml | Standard Deviation 324.46 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 322573 pg/ml | Standard Deviation 249585 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 269437 pg/ml | Standard Deviation 225974 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 6.4 pg/ml | Standard Deviation 2.5 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 671.0 pg/ml | Standard Deviation 349.68 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 6.4 pg/ml | Standard Deviation 3.04 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 522.2 pg/ml | Standard Deviation 512.23 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 8.6 pg/ml | Standard Deviation 1.34 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 748.0 pg/ml | Standard Deviation 527.71 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 292165 pg/ml | Standard Deviation 163750 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 307758 pg/ml | Standard Deviation 206598 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 592.6 pg/ml | Standard Deviation 684.51 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 191820 pg/ml | Standard Deviation 123461 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 587.5 pg/ml | Standard Deviation 437.86 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 11.9 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 8.4 pg/ml | Standard Deviation 1.91 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 10.6 pg/ml | Standard Deviation 1.98 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 479.2 pg/ml | Standard Deviation 359.29 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 174960 pg/ml | Standard Deviation 171958 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 6.8 pg/ml | Standard Deviation 3.39 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 238304 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 600.0 pg/ml | Standard Deviation 529.4 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 7.3 pg/ml | Standard Deviation 3 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 302708 pg/ml | Standard Deviation 213685 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 710.1 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 298611 pg/ml | Standard Deviation 178683 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 297119 pg/ml | Standard Deviation 87426.7 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 669.4 pg/ml | Standard Deviation 608.96 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 250882 pg/ml | Standard Deviation 165972 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 6.6 pg/ml | Standard Deviation 3.01 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 511.0 pg/ml | Standard Deviation 496.32 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 9.7 pg/ml | Standard Deviation 5.09 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 804.5 pg/ml | Standard Deviation 577.55 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 234304 pg/ml | Standard Deviation 146086 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 258286 pg/ml | Standard Deviation 88746.3 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 326939 pg/ml | Standard Deviation 184808 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 336973 pg/ml | Standard Deviation 225077 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 437.7 pg/ml | Standard Deviation 268.81 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 542.3 pg/ml | Standard Deviation 400.82 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 617.6 pg/ml | Standard Deviation 481.63 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 653.6 pg/ml | Standard Deviation 339.01 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 621.1 pg/ml | Standard Deviation 409.65 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 13.4 pg/ml | Standard Deviation 5.86 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 8.7 pg/ml | Standard Deviation 2.84 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 6.8 pg/ml | Standard Deviation 2.19 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 7.1 pg/ml | Standard Deviation 2.05 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 9.1 pg/ml | Standard Deviation 2.29 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 236277 pg/ml | Standard Deviation 108993 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 265679 pg/ml | Standard Deviation 89033.4 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 656.6 pg/ml | Standard Deviation 579.52 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 190445 pg/ml | Standard Deviation 113478 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 17.2 pg/ml | Standard Deviation 9.83 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 648.7 pg/ml | Standard Deviation 482 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 212425 pg/ml | Standard Deviation 106195 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 8.9 pg/ml | Standard Deviation 3.54 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 980.7 pg/ml | Standard Deviation 656.43 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 183926 pg/ml | Standard Deviation 163333 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 20.1 pg/ml | Standard Deviation 12.45 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 1195.4 pg/ml | Standard Deviation 1390 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 538.9 pg/ml | Standard Deviation 421.35 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 13.6 pg/ml | Standard Deviation 9.77 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 754.8 pg/ml | Standard Deviation 683.82 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 230125 pg/ml | Standard Deviation 174311 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 16.5 pg/ml | Standard Deviation 13.95 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 22.0 pg/ml | Standard Deviation 25.07 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 295378 pg/ml | Standard Deviation 133164 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 311792 pg/ml | Standard Deviation 104827 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 22.3 pg/ml | Standard Deviation 19.56 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 871.9 pg/ml | Standard Deviation 1068.86 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 282944 pg/ml | Standard Deviation 196959 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 8.5 pg/ml | Standard Deviation 1.89 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 76.4 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1904.2 pg/ml | Standard Deviation 2559.16 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 7.1 pg/ml | Standard Deviation 1.91 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 1432.7 pg/ml | Standard Deviation 1566.42 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 671.6 pg/ml | Standard Deviation 997.74 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 7.0 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 634.6 pg/ml | Standard Deviation 874.12 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 340151 pg/ml | Standard Deviation 232305 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 19.9 pg/ml | Standard Deviation 20.49 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 486629 pg/ml | Standard Deviation 381351 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 62172.4 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 184332 pg/ml | Standard Deviation 59292.8 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 156793 pg/ml | Standard Deviation 108469 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 15.0 pg/ml | Standard Deviation 11.95 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: TGFb1 (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 73118.3 pg/ml | Standard Deviation 49778 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: VEGF-A (n=3, 2, 4, 3, 1, 4, 3, 1, 12) | 641.8 pg/ml | Standard Deviation 651.66 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: TGFb1 (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 66293.0 pg/ml | Standard Deviation 47427.2 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: VEGF-A (n=4, 3, 6, 3, 4, 8, 7, 6, 24) | 671.1 pg/ml | Standard Deviation 998.34 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: VEGF-A (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 802.5 pg/ml | Standard Deviation 880.22 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: TGFb1 (n=5, 5, 6, 3, 4, 8, 7, 6, 24) | 72635.0 pg/ml | Standard Deviation 69063 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: PLGF (n=3, 2, 6, 1, 3, 4, 3, 2, 18) | 8.3 pg/ml | Standard Deviation 2.39 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: TGFb1 (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 65275.6 pg/ml | Standard Deviation 48954.3 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D16H: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 22) | 8.9 pg/ml | Standard Deviation 3.66 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: VEGF-A (n=4, 5, 6, 3, 4, 6, 7, 4, 20) | 1078.9 pg/ml | Standard Deviation 1095.02 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: TGFb1 (n=4, 5, 6, 3, 4, 6, 7, 5, 20) | 65483.2 pg/ml | Standard Deviation 35965.8 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: TGFb1 (n=5, 5, 2, 3, 4, 4, 5, 5, 17) | 95074.9 pg/ml | Standard Deviation 92796.5 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C2D1: VEGF-A (n=3, 2, 6, 3, 4, 5, 5, 2, 20) | 1064.3 pg/ml | Standard Deviation 2200.07 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: VEGF-A (n=4, 5, 6, 3, 3, 8, 7, 6, 24) | 613.5 pg/ml | Standard Deviation 984.96 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | Baseline: PLGF (n=4, 3, 5, 3, 2, 7, 6, 5, 21) | 13.4 pg/ml | Standard Deviation 5.27 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | EOT: PLGF (n=5, 4, 2, 2, 2, 3, 2, 4, 14) | 7.8 pg/ml | Standard Deviation 3.3 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C1D22: PLGF (n=4, 5, 6, 2, 3, 6, 6, 4, 18) | 8.4 pg/ml | Standard Deviation 3.28 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Placental Growth Factor (PLGF), Transforming Growth Beta 1 (TGFB1), Vascular Endothelial Growth Factor A (VEGF-A)]: Part 1 and Part 2 | C3D1: PLGF (n=3, 2, 3, 1, 1, 4, 2, 1, 10) | 6.9 pg/ml | Standard Deviation 1.92 |
Other Pre-specified
Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2
Plasma concentrations of soluble proteins (VEGF-C, VEGF-d, VEGFR1) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
Time frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
Population: Soluble protein biomarker analysis set included all participants who received at least one dose of study drug with a baseline (pre-dose C1D1) or screening biomarker result, and at least one on-treatment biomarker result for at least one biomarker. n signifies those participants who were evaluable at specific time-point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1521.1 pg/ml | Standard Deviation 863.1 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | 217.8 pg/ml | Standard Deviation 175.08 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 125.2 pg/ml | Standard Deviation 57.71 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 140.0 pg/ml | Standard Deviation 102.64 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 97.7 pg/ml | Standard Deviation 45.58 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 63.0 pg/ml | Standard Deviation 24.69 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 128.2 pg/ml | Standard Deviation 82.17 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 102.1 pg/ml | Standard Deviation 40.47 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 98.6 pg/ml | Standard Deviation 45.7 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 1377.6 pg/ml | Standard Deviation 2854.5 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 86.7 pg/ml | Standard Deviation 58.88 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 157.8 pg/ml | Standard Deviation 47.72 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1259.0 pg/ml | Standard Deviation 640.63 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1259.9 pg/ml | Standard Deviation 763.65 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 82.0 pg/ml | Standard Deviation 56.92 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1276.2 pg/ml | Standard Deviation 830.02 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 896.2 pg/ml | Standard Deviation 257.64 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1482.0 pg/ml | Standard Deviation 661.38 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1787.2 pg/ml | Standard Deviation 1467.67 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 1544.2 pg/ml | Standard Deviation 952.69 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | 139.8 pg/ml | — |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 85.7 pg/ml | Standard Deviation 40.52 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 110.1 pg/ml | Standard Deviation 55.86 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 102.8 pg/ml | — |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 2659.5 pg/ml | Standard Deviation 3611.41 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2365.6 pg/ml | Standard Deviation 2277.7 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 1556.8 pg/ml | — |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1463.6 pg/ml | Standard Deviation 813.87 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 316.4 pg/ml | Standard Deviation 561.02 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 41.8 pg/ml | Standard Deviation 7.71 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 129.4 pg/ml | — |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 325.0 pg/ml | Standard Deviation 545 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1826.2 pg/ml | Standard Deviation 1660.36 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 230.0 pg/ml | Standard Deviation 262.82 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1554.8 pg/ml | Standard Deviation 968.88 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 216.1 pg/ml | Standard Deviation 302.01 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 2218.0 pg/ml | Standard Deviation 2141.83 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 80.8 pg/ml | Standard Deviation 26.11 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 102.2 pg/ml | Standard Deviation 27.4 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 129.1 pg/ml | Standard Deviation 129.05 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 73.0 pg/ml | Standard Deviation 27.37 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | 100.2 pg/ml | Standard Deviation 64.49 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | NA pg/ml | — |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1694.0 pg/ml | Standard Deviation 1200.02 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1862.7 pg/ml | Standard Deviation 1422.39 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 1627.6 pg/ml | Standard Deviation 1133.17 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1873.7 pg/ml | Standard Deviation 1363.68 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1954.2 pg/ml | Standard Deviation 1737.3 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 118.1 pg/ml | Standard Deviation 65.01 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 200.2 pg/ml | Standard Deviation 241.23 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 181.8 pg/ml | Standard Deviation 207.89 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 464.1 pg/ml | Standard Deviation 611.85 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 109.5 pg/ml | Standard Deviation 34.95 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 412.9 pg/ml | Standard Deviation 389.4 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 209.0 pg/ml | Standard Deviation 148 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1393.9 pg/ml | Standard Deviation 371.4 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1300.9 pg/ml | Standard Deviation 623.64 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 79.2 pg/ml | Standard Deviation 27.82 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 258.4 pg/ml | Standard Deviation 336.53 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 81.9 pg/ml | Standard Deviation 37.78 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 82.3 pg/ml | Standard Deviation 45.18 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1289.9 pg/ml | Standard Deviation 633.94 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 60.1 pg/ml | — |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 146.0 pg/ml | Standard Deviation 129.9 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 1376.2 pg/ml | Standard Deviation 468.11 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 244.4 pg/ml | Standard Deviation 304.26 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 75.5 pg/ml | — |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | NA pg/ml | — |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 130.1 pg/ml | Standard Deviation 74.1 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1359.8 pg/ml | Standard Deviation 590.91 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1453.6 pg/ml | Standard Deviation 469.17 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 75.3 pg/ml | Standard Deviation 20.82 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 262.3 pg/ml | Standard Deviation 261.24 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 386.2 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 195.5 pg/ml | Standard Deviation 22.56 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 200.7 pg/ml | Standard Deviation 55.58 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1584.0 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 656.3 pg/ml | Standard Deviation 1160.02 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 2181.2 pg/ml | Standard Deviation 1622.16 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 2277.6 pg/ml | Standard Deviation 2283.7 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 1916.3 pg/ml | Standard Deviation 1499.55 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 151.4 pg/ml | Standard Deviation 67.03 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 187.6 pg/ml | Standard Deviation 8.84 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | 72.5 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1400.7 pg/ml | Standard Deviation 634.61 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 215.9 pg/ml | Standard Deviation 236.35 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 377.0 pg/ml | Standard Deviation 372.66 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 173.1 pg/ml | Standard Deviation 110.45 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2073.3 pg/ml | Standard Deviation 1258.05 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 146.8 pg/ml | Standard Deviation 108.75 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 86.1 pg/ml | Standard Deviation 25.17 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 118.9 pg/ml | Standard Deviation 22.12 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 77.8 pg/ml | Standard Deviation 30.55 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 2638.6 pg/ml | Standard Deviation 3254.13 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 56.4 pg/ml | Standard Deviation 22.5 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 78.1 pg/ml | Standard Deviation 24.17 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 2831.2 pg/ml | Standard Deviation 3980.28 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2421.0 pg/ml | Standard Deviation 2415.95 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 2557.3 pg/ml | Standard Deviation 3427.6 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 3876.5 pg/ml | Standard Deviation 5419.26 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 131.8 pg/ml | Standard Deviation 21.49 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | 93.6 pg/ml | Standard Deviation 38.86 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 103.8 pg/ml | Standard Deviation 45.97 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 2079.0 pg/ml | Standard Deviation 1987.67 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 50.3 pg/ml | Standard Deviation 26.44 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 77.5 pg/ml | Standard Deviation 39.81 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 116.9 pg/ml | Standard Deviation 62.28 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 79.6 pg/ml | Standard Deviation 62.56 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 130.9 pg/ml | Standard Deviation 78.92 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 92.7 pg/ml | Standard Deviation 60.15 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 138.0 pg/ml | Standard Deviation 112.15 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1282.9 pg/ml | Standard Deviation 308.22 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1333.5 pg/ml | Standard Deviation 404.55 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 362.6 pg/ml | Standard Deviation 525.74 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 219.5 pg/ml | Standard Deviation 195.62 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 388.4 pg/ml | Standard Deviation 351.79 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 1634.0 pg/ml | Standard Deviation 741.59 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 80.4 pg/ml | Standard Deviation 24.55 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 85.5 pg/ml | Standard Deviation 23.49 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1487.3 pg/ml | Standard Deviation 654.83 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 365.3 pg/ml | Standard Deviation 267.06 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1100.3 pg/ml | Standard Deviation 395.55 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 179.1 pg/ml | Standard Deviation 153 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1464.0 pg/ml | Standard Deviation 959.39 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | 90.5 pg/ml | — |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 127.9 pg/ml | Standard Deviation 91.93 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 114.9 pg/ml | Standard Deviation 43.61 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 283.3 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 1144.6 pg/ml | Standard Deviation 214.88 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 209.0 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 1031.1 pg/ml | Standard Deviation 285.11 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 1191.6 pg/ml | Standard Deviation 407.2 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1025.5 pg/ml | Standard Deviation 132.44 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 193.8 pg/ml | Standard Deviation 42.02 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 1470.1 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 1093.7 pg/ml | Standard Deviation 308.36 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 120.2 pg/ml | Standard Deviation 63.8 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 200.4 pg/ml | Standard Deviation 119.61 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 134.8 pg/ml | Standard Deviation 83.44 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 149.3 pg/ml | Standard Deviation 95.67 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 195.3 pg/ml | Standard Deviation 164.87 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 164.5 pg/ml | Standard Deviation 89.31 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 175.3 pg/ml | Standard Deviation 138.87 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | NA pg/ml | — |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGFR1 (n= 4, 5, 6, 3, 3, 5, 7, 4, 20) | 187.6 pg/ml | Standard Deviation 80.1 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGFR1 (n= 4, 3, 6, 3, 4, 8, 6, 6, 23) | 251.7 pg/ml | Standard Deviation 306.54 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-C (n= 2, 1, 2, 1, 2, 4, 4, 1, 11) | 201.4 pg/ml | Standard Deviation 91.96 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGFR1 (n= 5, 5, 6, 3, 4, 7, 7, 6, 23) | 243.6 pg/ml | Standard Deviation 128.59 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-C (n= 2, 2, 4, 2, 2, 5, 5, 4, 13) | 144.2 pg/ml | Standard Deviation 40.73 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-d (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 2011.1 pg/ml | Standard Deviation 988.62 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-d (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 2094.4 pg/ml | Standard Deviation 837.78 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGFR1 (n= 5, 5, 2, 2, 4, 4, 4, 5, 17) | 242.4 pg/ml | Standard Deviation 140.35 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | EOT: VEGF-C (n= 5, 4, 0, 1, 2, 3, 4, 5, 10) | 186.1 pg/ml | Standard Deviation 91.79 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGF-C (n= 2, 1, 2, 0, 1, 3, 1, 0, 8) | 190.5 pg/ml | Standard Deviation 71.75 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGF-d (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 1957.2 pg/ml | Standard Deviation 963.83 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-C (n= 3, 5, 4, 2, 2, 4, 4, 4, 12) | 154.1 pg/ml | Standard Deviation 85.63 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D22: VEGF-d (n= 4, 5, 6, 3, 4, 6, 7, 5, 19) | 2375.2 pg/ml | Standard Deviation 1506.25 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C1D16H: VEGF-d (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 2142.8 pg/ml | Standard Deviation 1494.28 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C3D1: VEGFR1 (n= 3, 2, 4, 3, 1, 4, 2, 1, 12) | 236.1 pg/ml | Standard Deviation 245.35 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-C (n= 3, 1, 3, 2, 2, 4, 4, 4, 15) | 123.1 pg/ml | Standard Deviation 59.79 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | Baseline: VEGF-d (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 2127.8 pg/ml | Standard Deviation 1620.79 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor C (VEGF-C), Vascular Endothelial Growth Factor-d (VEGF-d), Vascular Endothelial Growth Factor Receptor Type 1 (VEGFR1)]: Part 1 and Part 2 | C2D1: VEGFR1 (n= 3, 1, 6, 3, 4, 5, 5, 2, 20) | 656.5 pg/ml | Standard Deviation 2066.54 |
Other Pre-specified
Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2
Plasma concentrations of soluble proteins (VEGFR2, VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity.
Time frame: Baseline (pre-dose of C1D1), C1D1 6 hours post dosing, C1D22, C2D1, C3D1 and end of treatment (Day 490)
Population: Soluble Protein Biomarker Analysis Set included all participants who received at least one dose of study drug with a baseline (pre-dose C1D1) or screening biomarker result, and at least one on-treatment biomarker result for at least one biomarker. n signifies those participants who were evaluable at specific time-point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 8414.2 pg/ml | Standard Deviation 3145.86 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 456367 pg/ml | Standard Deviation 205119 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 8780.4 pg/ml | Standard Deviation 4855.85 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 6699.4 pg/ml | Standard Deviation 3398.5 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 456664 pg/ml | Standard Deviation 83808.5 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 418199 pg/ml | Standard Deviation 135460 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 403555 pg/ml | Standard Deviation 118261 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 7989.8 pg/ml | Standard Deviation 3208.34 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 486756 pg/ml | Standard Deviation 156161 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 8310.6 pg/ml | Standard Deviation 4171.13 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 421297 pg/ml | Standard Deviation 89735.8 |
| PF-03446962 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 9541.6 pg/ml | Standard Deviation 3903.58 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 8297.5 pg/ml | Standard Deviation 4291.01 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 283799 pg/ml | Standard Deviation 30962.7 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 417915 pg/ml | Standard Deviation 101370 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 8281.8 pg/ml | Standard Deviation 4500.81 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 396991 pg/ml | Standard Deviation 111696 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 9896.8 pg/ml | Standard Deviation 1626.91 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 335446 pg/ml | Standard Deviation 688.51 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 9672.8 pg/ml | Standard Deviation 4841.31 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 413223 pg/ml | Standard Deviation 111775 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 358829 pg/ml | Standard Deviation 70878.1 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 9372.8 pg/ml | Standard Deviation 1111.71 |
| PF-03446962 1 mg/kg | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 7069.9 pg/ml | Standard Deviation 5395.12 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 9191.5 pg/ml | Standard Deviation 2061.89 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 340605 pg/ml | Standard Deviation 106111 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 396443 pg/ml | Standard Deviation 324477 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 9884.4 pg/ml | Standard Deviation 3258.5 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 380689 pg/ml | Standard Deviation 189516 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 9057.3 pg/ml | Standard Deviation 1614.38 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 8834.8 pg/ml | Standard Deviation 1749.43 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 483165 pg/ml | Standard Deviation 166891 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 7490.4 pg/ml | Standard Deviation 5124.26 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 482016 pg/ml | Standard Deviation 227736 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 9736.1 pg/ml | Standard Deviation 1396.4 |
| PF-03446962 2 mg/kg : Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 376867 pg/ml | Standard Deviation 146099 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 282590 pg/ml | Standard Deviation 58032.4 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 278094 pg/ml | Standard Deviation 29688.1 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 10248.0 pg/ml | Standard Deviation 1886.86 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 306684 pg/ml | Standard Deviation 72478.1 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 9988.4 pg/ml | Standard Deviation 1704.87 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 299955 pg/ml | Standard Deviation 42094.9 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 11521.7 pg/ml | Standard Deviation 1822.45 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 10980.4 pg/ml | Standard Deviation 1881.48 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 272982 pg/ml | Standard Deviation 12015.1 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 282449 pg/ml | Standard Deviation 52144 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 10475.6 pg/ml | Standard Deviation 862.91 |
| PF-03446962 3 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 9354.7 pg/ml | Standard Deviation 2102.62 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 7180.0 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 9536.4 pg/ml | Standard Deviation 2527.39 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 7707.1 pg/ml | Standard Deviation 2003.97 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 8057.2 pg/ml | Standard Deviation 1948.44 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 6621.2 pg/ml | Standard Deviation 1637.27 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 8151.8 pg/ml | Standard Deviation 2508.61 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 336510 pg/ml | Standard Deviation 183465 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 301990 pg/ml | Standard Deviation 114920 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 335397 pg/ml | Standard Deviation 159853 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 326823 pg/ml | Standard Deviation 171815 |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 563837 pg/ml | — |
| PF-03446962 4.5 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 319223 pg/ml | Standard Deviation 117705 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 402326 pg/ml | Standard Deviation 127490 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 9289.2 pg/ml | Standard Deviation 2003.7 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 371861 pg/ml | Standard Deviation 130334 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 8016.8 pg/ml | Standard Deviation 1689.68 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 419244 pg/ml | Standard Deviation 54326.1 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 405426 pg/ml | Standard Deviation 135402 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 8912.0 pg/ml | Standard Deviation 2327.17 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 403432 pg/ml | Standard Deviation 164005 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 7902.7 pg/ml | Standard Deviation 2606.45 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 356012 pg/ml | Standard Deviation 127436 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 10018.0 pg/ml | Standard Deviation 2860.16 |
| PF-03446962 6.75 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 7526.1 pg/ml | Standard Deviation 1910.18 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 7727.3 pg/ml | Standard Deviation 3137.81 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 377133 pg/ml | Standard Deviation 109330 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 446291 pg/ml | Standard Deviation 293311 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 9230.3 pg/ml | Standard Deviation 4272.69 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 326291 pg/ml | Standard Deviation 81142 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 9784.5 pg/ml | Standard Deviation 2193.47 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 7712.5 pg/ml | Standard Deviation 2738.41 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 361958 pg/ml | Standard Deviation 106007 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 7500.6 pg/ml | Standard Deviation 2409.88 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 7771.7 pg/ml | Standard Deviation 3593.1 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 384832 pg/ml | Standard Deviation 157842 |
| PF-03446962 10 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 301489 pg/ml | Standard Deviation 85606.4 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 440490 pg/ml | Standard Deviation 118906 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 409280 pg/ml | Standard Deviation 166548 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 8567.2 pg/ml | Standard Deviation 222.95 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 9632.8 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 9572.0 pg/ml | Standard Deviation 2736.01 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 309162 pg/ml | — |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 375385 pg/ml | Standard Deviation 89006 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 8934.9 pg/ml | Standard Deviation 1266 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 9357.8 pg/ml | Standard Deviation 2845.47 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 330917 pg/ml | Standard Deviation 3323.61 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 8827.1 pg/ml | Standard Deviation 1458.2 |
| PF-03446962 15 mg/kg: Part 1 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 367493 pg/ml | Standard Deviation 104354 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR3 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 436507 pg/ml | Standard Deviation 130015 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR3 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 401286 pg/ml | Standard Deviation 120518 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR2 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 7147.6 pg/ml | Standard Deviation 2735.63 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D22: VEGFR3 (n= 4, 5, 6, 3, 4, 6, 7, 5, 20) | 439596 pg/ml | Standard Deviation 117856 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR2 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 8151.0 pg/ml | Standard Deviation 2254.12 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR2 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 6708.1 pg/ml | Standard Deviation 2314.78 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C1D16H: VEGFR3 (n= 4, 3, 6, 3, 4, 8, 7, 6, 24) | 427567 pg/ml | Standard Deviation 133307 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR2 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 6495.9 pg/ml | Standard Deviation 2172.45 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C3D1: VEGFR2 (n= 3, 2, 4, 3, 1, 4, 3, 1, 12) | 7087.9 pg/ml | Standard Deviation 2430.45 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | Baseline: VEGFR3 (n= 5, 5, 6, 3, 4, 8, 7, 6, 24) | 423268 pg/ml | Standard Deviation 152555 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | C2D1: VEGFR2 (n= 3, 2, 6, 3, 4, 5, 5, 2, 20) | 7468.4 pg/ml | Standard Deviation 2757.65 |
| PF-03446962 7 mg/kg: Part 2 | Soluble Protein Biomarker [Vascular Endothelial Growth Factor Receptor Type 2 (VEGFR2), Vascular Endothelial Growth Factor Receptor Type 3 (VEGFR3)]: Part 1 and Part 2 | EOT: VEGFR3 (n= 5, 5, 2, 3, 4, 4, 5, 5, 17) | 457457 pg/ml | Standard Deviation 144474 |
Other Pre-specified
Systemic Clearance(CL): Part 1 and Part 2
CL is a quantitative measure of the rate at which a drug substance is removed from the body. As per planned analysis, CL was summarized if at least 3 participants had reportable value.
Time frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962. Here N (Number of participants analyzed) signifies those who were evaluable for the measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| PF-03446962 | Systemic Clearance(CL): Part 1 and Part 2 | 0.07675 liter/hour (L/hr) | Standard Deviation 0.02318 |
| PF-03446962 1 mg/kg | Systemic Clearance(CL): Part 1 and Part 2 | 0.03469 liter/hour (L/hr) | Standard Deviation 0.00866 |
| PF-03446962 2 mg/kg : Part 1 | Systemic Clearance(CL): Part 1 and Part 2 | 0.04198 liter/hour (L/hr) | Standard Deviation 0.03927 |
| PF-03446962 3 mg/kg: Part 1 | Systemic Clearance(CL): Part 1 and Part 2 | NA liter/hour (L/hr) | — |
| PF-03446962 4.5 mg/kg: Part 1 | Systemic Clearance(CL): Part 1 and Part 2 | NA liter/hour (L/hr) | — |
| PF-03446962 6.75 mg/kg: Part 1 | Systemic Clearance(CL): Part 1 and Part 2 | 0.01861 liter/hour (L/hr) | Standard Deviation 0.00225 |
| PF-03446962 10 mg/kg: Part 1 | Systemic Clearance(CL): Part 1 and Part 2 | 0.01668 liter/hour (L/hr) | Standard Deviation 0.00482 |
| PF-03446962 15 mg/kg: Part 1 | Systemic Clearance(CL): Part 1 and Part 2 | 0.01169 liter/hour (L/hr) | Standard Deviation 0.01288 |
| PF-03446962 7 mg/kg: Part 2 | Systemic Clearance(CL): Part 1 and Part 2 | 0.01921 liter/hour (L/hr) | Standard Deviation 0.00507 |
Other Pre-specified
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2
Time frame: 0 hr (pre-dose),0.5,1,1.5,2,5,10,24 hr post-dose on Day (D) 1,3,5,8,11,15,22 of Cycle (C) 1, 0 hr,1 hr post-dose on Day 1 of subsequent cycles up to cycle 12, 28 days after last dose for dose (up to 3 months after last dose for >=2 mg/kg arms)
Population: Pharmacokinetic analysis set included all participants who received at least one dose of study drug and who had complete sampling for pharmacokinetic profiles for PF-03446962. Here N (Number of participants analyzed) signifies those who were evaluable for the measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| PF-03446962 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.50 hour |
| PF-03446962 1 mg/kg | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.58 hour |
| PF-03446962 2 mg/kg : Part 1 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.75 hour |
| PF-03446962 3 mg/kg: Part 1 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.50 hour |
| PF-03446962 4.5 mg/kg: Part 1 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.99 hour |
| PF-03446962 6.75 mg/kg: Part 1 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.75 hour |
| PF-03446962 10 mg/kg: Part 1 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.50 hour |
| PF-03446962 15 mg/kg: Part 1 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 3.34 hour |
| PF-03446962 7 mg/kg: Part 2 | Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-03446962: Part 1 and Part 2 | 1.77 hour |